Acessa Health

What Acessa Health does

Acessa Health develops and commercializes the Acessa Laparoscopic Fibroid Ablation system, a minimally-invasive, non-hormonal, uterine-sparing procedure for women with symptomatic uterine fibroids. The core technology delivers targeted radiofrequency heat energy through small abdominal incisions under laparoscopic and ultrasound guidance, ablating fibroids in situ and causing them to soften and shrink over time while preserving the uterus. The dedicated device platform is the Acessa ProVu System; the procedure treats intramural, submucosal, and subserosal fibroids of varying sizes in a single outpatient session lasting 1–2 hours, with most patients discharged the same day and returning to work in 4–5 days. Clinical claims include 94% symptom improvement and a 98% patient recommendation rate.

The company was founded in 2004 and is headquartered in Austin, Texas. Since 2020, Acessa has operated as a wholly-owned subsidiary of Hologic, Inc. (NASDAQ: HOLX), distributed exclusively through Hologic's GYN Surgical direct sales organization alongside complementary products such as NovaSure endometrial ablation, Sonata transcervical fibroid ablation, and the MyoSure tissue removal system. Revenue is generated through hardware and consumable sales to hospitals, ambulatory surgical centers, and outpatient facilities performing the procedure, with payments ultimately reimbursed by commercial insurers and Medicaid (prior authorization typically required). The standalone legal entity reports 1–10 employees; standalone revenue is not separately disclosed and is reported within Hologic's GYN Surgical segment, which has grown at a 7.6% CAGR over the past decade. Patient acquisition is supported through direct-to-consumer marketing (#KnowYourU campaign, Change the Cycle blog, Symptoms Quiz, Nurse Advocate program) and a Find a Physician locator connecting patients with Acessa-trained gynecologists.

Name

Acessa Health

Legal name

Acessa Health

Website

https://acessaprocedure.com

Company type

Private

Founded year

2004

Operating status

Acquired

Headcount range

1–10 employees

Short description

Acessa Health develops the Acessa Laparoscopic Fibroid Ablation system, a minimally-invasive, uterine-sparing radiofrequency procedure for women with symptomatic uterine fibroids. Since 2020, the company has operated as a wholly-owned subsidiary of Hologic, distributed through Hologic's GYN Surgical division to trained gynecologists and hospitals.

Ownership category

akta.pro rank

Product category

Gynecological Surgical Medical Devices

NAICS

Freestanding Ambulatory Surgical and Emergency Centers (621493), Offices of Physicians (62111)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

akta.pro secondary industry

Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy) (HLAKAJAF)

Keywords

• Laparoscopic fibroid ablation
• Radiofrequency ablation system
• Gynecological surgical devices
• Uterine fibroid treatment
• Minimally invasive women's health

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Medical Device Sales - Fibroid Treatment Products: Acessa generates revenue through the sale of its laparoscopic fibroid ablation procedure and related devices. As a subsidiary of Hologic, the product is distributed through Hologic's GYN Surgical business unit which has achieved a 7.6% CAGR over the past decade. Revenue comes from healthcare providers purchasing the Acessa system and consumables for performing the procedure, with insurance reimbursement from both commercial insurers and Medicaid.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Acessa Health develops and commercializes the Acessa Laparoscopic Fibroid Ablation system, a minimally-invasive medical device that uses targeted radiofrequency heat energy to shrink symptomatic uterine fibroids while preserving the uterus. The outpatient procedure is performed by trained gynecologists through small abdominal incisions, treating intramural, submucosal, and subserosal fibroids in a single session with same-day discharge and 4-5 day recovery. The system is sold to healthcare providers and integrated within Hologic's GYN Surgical portfolio following Hologic's 2020 acquisition.

Product overview

Acessa Health, acquired by Hologic in 2020, offers the Acessa Laparoscopic Fibroid Ablation system—a minimally-invasive, uterine-sparing procedure for symptomatic uterine fibroids. The core Acessa product uses targeted radiofrequency heat energy delivered through small abdominal incisions to shrink fibroids while preserving the uterus. The Acessa ProVu system is the specific device platform used during the procedure. Acessa fits within Hologic's broader GYN Surgical portfolio that includes NovaSure endometrial ablation, Sonata transcervical fibroid ablation, and MyoSure tissue removal system, enabling comprehensive fibroid and abnormal uterine bleeding treatment options across different patient needs and fibroid types (intramural, submucosal, and subserosal).

Differentiator

Problem solved

Functional benefit

Products and services

• Acessa Laparoscopic Fibroid Ablation A minimally-invasive, non-hormonal, uterine-sparing procedure that uses targeted radiofrequency heat energy to shrink symptomatic uterine fibroids. Performed by trained gynecologists as an outpatient procedure through three small abdominal incisions, with patients typically returning to work in 4-5 days and 94% reporting symptom improvement.
• Acessa ProVu System The medical device platform used during the Acessa laparoscopic procedure. Designed to identify and shrink symptomatic uterine fibroids through targeted heat ablation, performed by trained physicians during laparoscopic surgery under general anesthesia.

Quantifiable outcome

• 94% of patients said the procedure helped with their symptoms
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• HologicflagshipStrategic or Co-development Partner · 1 January 2020Hologic acquired Acessa Health in 2020 as part of an inorganic growth strategy to expand its fibroid treatment portfolio. The acquisition added Acessa's laparoscopic radiofrequency ablation system to Hologic's GYN Surgical portfolio, complementing existing products like MyoSure tissue removal, Fluent fluid management, NovaSure endometrial ablation, and Sonata transcervical fibroid ablation. Acessa was further integrated with the January 2025 acquisition of Gynesonics, strengthening Hologic's position in the fibroid treatment market.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Gynesonics: Developer of the Sonata transcervical fibroid ablation system, a directly competing minimally invasive fibroid ablation technology. Now also a Hologic company (acquired January 2025), making it a sibling and direct substitute within the same GYN Surgical portfolio.
• InSightec: Maker of ExAblate, an MR-guided focused ultrasound system for non-invasive fibroid ablation. Competes with Acessa on the same clinical decision (fibroid ablation) via a fundamentally different but adjacent ablation modality.

Broad incumbents

• Medtronic: Large medical device incumbent with gynecologic surgery and energy-based surgical instruments. Competes broadly for GYN operating-room contracts and physician adoption against Acessa-enabled procedures.
• CONMED: Electrosurgery and laparoscopic instrumentation company whose ablation and energy devices are sold into the same GYN OR accounts that perform Acessa procedures.
• Hologic: Parent company and incumbent in GYN Surgical. Operates overlapping fibroid and AUB treatments (NovaSure, MyoSure, Sonata, Fluent) that compete with Acessa for the same physician customers and patient indications.
• CooperSurgical: Broad women's health medical device company offering fibroid and hysteroscopic surgery products (including tissue removal systems) that compete with Acessa for gynecologist share-of-wallet and OR utilization.
• Boston Scientific: Diversified medical device company with hysteroscopic and gynecologic surgery offerings that overlap with Acessa's surgical fibroid treatment category, often competing for the same hospital capital budgets.
• Stryker: Surgical instruments and OR equipment supplier, including laparoscopic and electrosurgical platforms used in fibroid surgery. Comparable as a competing supplier to hospitals performing minimally invasive gynecologic procedures.

Others

• Karl Storz: Leading manufacturer of rigid endoscopes, laparoscopes, and the trocars used in laparoscopic fibroid surgery. Acts as an enabling infrastructure supplier to the Acessa procedure rather than a direct competitor.

Emerging players

• AngioDynamics: Developer of radiofrequency and other ablation technologies for soft tissue. While not focused on gynecology, its RFA platform represents an adjacent ablation modality that could enter the fibroid treatment space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Acessa
• YouTubeyoutube.com/channel/UChrzlPhyLwmBUgjFAUHc0qQ
• Facebookfacebook.com/AcessaProcedure
• LinkedInlinkedin.com/company/acessahealth
• Instagraminstagram.com/knowyouru

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acessa Health